⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8987275 | 0.62 | — | — | |
| SCHEMBL375314 | 0.62 | — | — | |
| SCHEMBL1203 | 0.62 | — | — | |
| SCHEMBL555850 | 0.61 | — | — | |
| SCHEMBL22262893 | 0.61 | — | — | |
| SCHEMBL10614207 | 0.58 | — | — | |
| SCHEMBL285899 | 0.58 | — | — | |
| SCHEMBL25204735 | 0.57 | — | — | |
| SCHEMBL21590148 | 0.57 | — | — | |
| SCHEMBL21722216 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | claimed |
| CN-108473471-A | Substituted thiourocystine derivatives as androgen receptor antagonists | 詹森药业有限公司 | 2018-08-31 | — | — | CN | claimed |
| CN-104470925-B | Imidazo-triazine formonitrile HCN as kinase inhibitor | 百时美施贵宝公司 | 2017-12-05 | — | — | CN | claimed |
| CN-107406434-A | As 5 HT4The amide compound of receptor stimulating agent | 苏文生命科学有限公司 | 2017-11-28 | — | — | CN | claimed |
| US-20170298043-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD. (GB) | 2017-10-19 | — | — | US | claimed |
| CN-105308045-B | New 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds | 豪夫迈·罗氏有限公司 | 2017-05-17 | — | — | CN | claimed |
| CN-105308045-A | New 3,4-dihydro-2H-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds | HOFFMANN LA ROCHE | 2016-02-03 | — | — | CN | claimed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | claimed |
| US-20200361905-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS R&D LTD (GB) | 2020-11-19 | — | — | US | disclosed |
| US-10696652-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD. (GB) | 2020-06-30 | — | — | US | disclosed |
| CN-106068262-B | Quinazoline derivant and preparation method thereof and application in medicine | HAISCO PHARMACEUTICAL GROUP INC. (CN) | 2019-10-29 | — | — | CN | disclosed |
| CN-110143950-A | Medical compounds | 西雅图遗传学公司 | 2019-08-20 | — | — | CN | disclosed |
| CN-110141570-A | Medical compounds | 西雅图遗传学公司 | 2019-08-20 | — | — | CN | disclosed |
| CN-106170288-B | Pharmaceutical compounds | 西雅图遗传学公司 | 2019-07-19 | — | — | CN | disclosed |
| CN-103221392-A | Bridged spiro[2.4]heptane ester derivatives | ACTELION PHARMACEUTICALS LTD | 2013-07-24 | — | — | CN | disclosed |
| US-20130005709-A1 | SULFONE COMPOUNDS AS 5-HT6 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2013-01-03 | — | — | US | disclosed |
| EP-2294065-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | Vernalis (R&D) Ltd. (GB) | 2011-03-16 | — | — | EP | disclosed |
| US-20110021498-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | US | disclosed |
| WO-2011010083-A1 | INDOLYL-PYRIDONE DERIVATIVES | VERNALIS (R & D) LTD (GB) | 2011-01-27 | — | — | WO | disclosed |
| WO-2009093012-A1 | INDOLYL- PYRIDONE DERIVATIVES HAVING CHECKPOINT KINASE 1 INHIBITORY ACTIVITY | VERNALIS (R & D) LTD (GB) | 2009-07-30 | — | — | WO | disclosed |